Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by severe lung inflammation and difficulty maintaining normal oxygen levels. It accounts for approximately 25%
Somnus’ CEO Dr Tim Craft was recently in the USA speaking at theAnnual Conference of the Society for Technology in Anaesthesia (STA). We asked him
The phrase “First Do No Harm” is a Latin quote (Primum non nocere) often (though with little evidence) attributed to Hippocrates and applied to an
Propofol is the first-line sedative recommended for patients in ICU, especially those needing help with their breathing from a ventilator. The challenge is that it
For years, midazolam (a benzodiazepine) was the preferred drug to be used with patients requiring sedation on ICU. More recently, though, numerous studies have been
Somnus is developing rapid, point-of-care propofol measuring technologies but is there another drug that could be used instead? Traditionally, benzodiazepines such as midazolam were the
The first report from Baroness Hallett, who is chairing the Covid public inquiry, has been published. In it she says, “it is not a question
Clinicians at the Institute of Liver and Biliary Sciences, Delhi, India have published the findings of their prospective study aimed at determining the target concentration
Somnus has developed the first ever antibody for propofol. This means that it will soon be possible to measure propofol in real time and optimise
Somnus Scientific has agreed a collaborative partnership with Life Science Group (LSG) and Creonate Manufacturing for the next phase of product development. As part of
Somnus is also a Scale-Up member of SETSquared.
Somnus Scientific Ltd
Stockland
Beechen Cliff Rd
Bath
BA2 4QR
